Glaxo fires some China staff for malpractice amid stepped-up surveillance

With GlaxoSmithKline's ($GSK) China operations under investigation amid bribery allegations, the company is keeping its employees there under a more watchful eye. As Reuters reports, that extra surveillance helped turn up failures to comply with expense rules, leading to the firing of some staffers for malpractice. "Where we have found potential issues, we are thoroughly reviewing them and have withheld incentive payments where appropriate," a Glaxo spokesman told the news service. More

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.